NCT00810576 · ADVERSE EVENTS

Adverse events

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma · Source last updated 2012-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 13 Months
Other-event reporting threshold: 1%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Vorinostat + Bortezomib Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m\^2 intravenously on Days 1, 4, 8, 11.	0 / 1	0 / 1	Not reported / Not reported

Group identifiers: EG000: Vorinostat + Bortezomib

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

description
Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m\^2 intravenously on Days 1, 4, 8, 11.
id
EG000
other Num Affected
0
other Num At Risk
1
serious Num Affected
0
serious Num At Risk
1
title
Vorinostat + Bortezomib

frequency Threshold

time Frame

13 Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice